Sanomigran 1.5mg Tablets

Ülke: İrlanda

Dil: İngilizce

Kaynak: HPRA (Health Products Regulatory Authority)

Aktif bileşen:

Pizotifen

Mevcut itibaren:

Phoenix Labs

ATC kodu:

N02CX; N02CX01

INN (International Adı):

Pizotifen

Doz:

1.5 milligram(s)

Farmasötik formu:

Coated tablet

Uygulama yolu:

oral use

Paketteki üniteler:

carton containing 28 tablets

Reçete türü:

Product subject to prescription which may be renewed (B)

Terapötik grubu:

antimigraine drug

Terapötik alanı:

Other antimigraine preparations; pizotifen

Terapötik endikasyonlar:

Prophylactic treatment of recurrent vascular headaches, including classical migraine, common migraine and cluster headache (periodic migrainous neuralgia). Sanomigran is not effective in relieving migraine attacks once in progress. The International Classification of Headache Disorders 2nd edition (ICHD-II) are standard classifications of headache used by healthcare professionals and describe the above-mentioned disorders as follows: prophylactic treatment of recurrent migraine headache with or without aura and of cluster headache.

Yetkilendirme durumu:

Not marketed

Yetkilendirme tarihi:

1994-09-07

Ürün özellikleri

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Sanomigran 1.5mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 1.5 mg pizotifen as malate.
Excipients - contains Lactose Monohydrate 136.425mg and sucrose
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Coated tablet
Ivory/yellow, sugar-coated, bi-convex tablets, printed ‘SMG 1.5’
on one face.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Prophylactic treatment of recurrent vascular headaches, including
classical migraine, common migraine and cluster
headache (periodic migrainous neuralgia).
Sanomigran is not effective in relieving migraine attacks once in
progress.
The International Classification of Headache Disorders 2
nd
edition (ICHD-II) are standard classifications of headache
used by healthcare professionals and describe the above-mentioned
disorders as follows:
prophylactic treatment of
recurrent migraine headache with or without aura and of cluster
headache.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Oral administration.
_Adults_
Starting with 0.5mg daily, the dosage should be progressively
increased.
Dose is usually 1.5 mg daily.
This may be
taken as a single dose at night or in three divided doses, using 0.5
mg tablets or 1.5 mg tablets as appropriate.
Dosage
should be adjusted to individual patients'
requirements up to a maximum of 4.5 mg daily. Up to 3 mg may be given
as a
single daily dose.
_Children over 12 years:_
Starting with 0.5mg daily, the dosage should be progressively
increased.
Dose is up to 1.5 mg daily, usually as a
divided dose.
Use of the 1.5 mg tablets is not recommended but up to 1 mg has been
given as a single daily dose at
night. 0.5 mg tablets may be used.
_Use in the elderly_
Clinical work with Sanomigran has not shown that elderly patients
require different dosages from younger patients.
_Special populations_
Renal and hepatic impairment
Caution is required in patients with renal or hepatic impairment and
dosage adjustment may be necessary (see section
5.2 P